XCSport体育
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
XCSport体育:Clinical Trial
Science & Technology
R&D Result
Innovation Centre
XCSport体育:Technology Platform
XCSport体育:Quality Management
XCSport体育:Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
XCSport体育:Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
Multi-media
XCSport体育:Media Reports
XCSport体育:Media Enquiry
Careers
Talent Philosophy
XCSport体育:Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
XCSport体育:Customer Message
Privacy
XCSport体育:Legal Statement
Compliance
EN
简体
EN
繁體
Home
XCSport体育:About Henlius
Company Profile
XCSport体育:Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
XCSport体育:Marketed Products
Products in R&D
Clinical Trial
Science & Technology
XCSport体育:R&D Result
Innovation Centre
XCSport体育:Technology Platform
Quality Management
Manufacturing
XCSport体育:Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
XCSport体育:Media Enquiry
Careers
XCSport体育:Talent Philosophy
XCSport体育:Staff Life
Training and Development
Job Opportunities
Contact Us
XCSport体育:Contact Information
XCSport体育:Customer Message
Privacy
Legal Statement
Compliance
搜索
Be the most trusted biotech company
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
XCSport体育:Popular Science
Highlights
Download
XCSport体育:Media Reports
XCSport体育:Media Enquiry
2024-12-28
HANSIZHUANG Sets Sail in Indonesia Market
2024-12-27
FDA Grants Fast Track Designation to Henlius’ EGFR-Targeting ADC HLX42 for NSCLC Patients with Disease Progression on EGFR Targeted Therapies
2024-12-22
Henlius Passes Its Second EU GMP Inspection
2024-12-13
First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Ipilimumab Biosimilar HLX13
2024-12-12
The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of non-squamous NSCLC Accepted by the NMPA
2024-12-05
Henlius Receives "Listed Enterprises 2023" Award from Bloomberg Businessweek/Chinese Edition
2024-12-04
Results from Four Phase 1/2 Clinical Trials of Henlius’ Innovative Products Released at 2023 ESMO Asia
2024-12-04
Results from the Phase 2 Clinical Trial of Henlius BRAF Inhibitor HLX208 for the Treatment of LCH and/or ECD Released at 2023 ESMO Asia
2024-12-04
Results of the Asian Subgroup in Phase 3 Clinical Study of Novel Anti-PD-1 mAb HANSIZHUANG for the First-Line Treatment of sqNSCLC Released at ESMO Asia 2023
1
2
3
...
8